Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001213900-25-043211
Filing Date
2025-05-14
Accepted
2025-05-14 14:59:40
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 9311
2 JOINT FILING AGREEMENT ea024218501ex99-1_alaunos.htm EX-99.1 4571
  Complete submission text file 0001213900-25-043211.txt   15784
Mailing Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Subject) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-79364 | Film No.: 25944714
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 120 NEWPORT CENTER DRIVE STE. 250 NEWPORT BEACH CA 92660
Business Address 120 NEWPORT CENTER DRIVE STE. 250 NEWPORT BEACH CA 92660 888-445-4886
PMGC CAPITAL LLC (Filed by) CIK: 0002068010 (see all company filings)

EIN.: 331978501 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SCHEDULE 13D